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Available online 3 August 2016AbstractAs a bisphosphonate, minodronate (MIN) is one of the strongest inhibitors of bone resorption. However, there have been no reports directly
comparing the antiresorptive effects of monthly MIN with those of monthly risedronate (RIS). We enrolled 30 cases of osteoporosis (OP; 16 in
the MIN group [mean age: 68.2 years] and 14 in the RIS group [mean age: 68.1 years]) to investigate the early effects of treatment by monthly
MIN or RIS over a 4-month period using bone turnover marker values. Only female patients were enrolled to avoid gender bias. Urinary cross-
linked N-telopeptide of type I collagen (NTX) before treatment and at 1, 2, and 4 months of therapy, as well as serum bone alkaline phosphatase
and alkaline phosphatase before treatment and at 4 months afterwards, were evaluated. All bone turnover marker values were significantly
decreased at 4 months in both groups. The changes in urinary NTX at the study end point for RIS and MIN were 30.1% and 63.1%,
respectively. From 2 months of treatment, the antiresorptive effects on urinary NTX by MIN were significantly higher than those by RIS,
indicating that MIN more immediately and strongly inhibited bone absorption. Thus, monthly MIN seems to suppress bone resorption faster and
more strongly than RIS in OP treatment.
© 2016 The Korean Society of Osteoporosis. Publishing services by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Bisphosphonates (BPs) are the first-line drugs in osteopo-
rosis (OP) treatment [1]. The goal of OP management is the
prevention of fractures and ultimately death caused directly or
indirectly by bone fragility fractures; indeed, mortality rate
was decreased by BP treatment in patients with femoral neck
fractures [2,3], and OP therapy using BPs reduced mortality
risk in the elderly [4,5].
First launched outside of Japan, alendronate (ALN) and
risedronate (RIS) are common BPs employed in OP treatment.* Corresponding author. Department of Orthopaedic Surgery, Shinshu Uni-
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(http://creativecommons.org/licenses/by-nc-nd/4.0/).These drugs were approved in Japan in 2001 and have been
prescribed in once-daily, -weekly, and -monthly regimens.
Currently, weekly and monthly BP courses are most widely
used for OP [1]. Moreover, Iwamoto et al. [6] reported that
greater than 65% of Japanese osteoporotic patients prefer
monthly BPs to daily or weekly BPs.
Developed and recently approved in Japan in 2009, min-
odronate (minodronic acid hydrate; MIN) is the strongest in-
hibitor of bone resorption among commercially available BPs
[7]. MIN is a potent nitrogen-containing BP manufactured in
Japan [8] that has been demonstrated to prevent vertebral
fractures in Japanese osteoporotic patients based on a placebo-
controlled phase III trial [9].
It is very difficult to directly evaluate the effects of BP
therapy on the prevention of fractures and ultimate death
caused by fractures. Another means of estimating the efficacylsevier B.V. This is an open access article under the CC BY-NC-ND license
Fig. 1. Value changes of urinary NTX before treatment and at 1, 2, and 4
months of therapy in MIN and RIS groups. Data are shown as average ± SE. *:
statistically significant based on one-sided paired t-tests with Bonferroni
correction. #: statistically significant according to one-sided Welch's t-tests.
MIN (50 mg/monthly), minodronate; RIS, risedronate (75 mg/monthly); NTX,
cross-linked N-telopeptide of type I collagen.
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although a relatively long follow-up period is required to
evaluate changes in BMD. Most OP treatments, including BPs,
augment BMD through the inhibition of bone resorption. The
antiresorptive effects induced by BPs appear in the early
period of administration and can be easily confirmed by the
measurement of bone turnover markers. Therefore, in the
short-term period of BP treatment, bone turnover markers
represent useful surrogate biomarkers to evaluate the thera-
peutic effects of BPs.
Nowadays, MIN and RIS are used as monthly BP options
for OP treatment in Japan. In a phase III study, the inhibitory
effects of these drugs on urinary cross-linked N-telopeptide of
type I collagen (NTX) at 3e6 months of monthly treatment
were over 50% and approximately 30%, respectively [10]. We
previously compared the early changes in bone turnover
markers between daily MIN and weekly RIS to reveal that
daily MIN more strongly inhibited bone turnover [8]. From the
results of these studies, the bone resorption-inhibiting effect of
MIN has become well recognized as stronger than that of RIS.
However, there have been no reports directly comparing the
inhibition of bone turnover caused by monthly MIN and RIS
regimes. We herein investigated the short-term treatment ef-
fects of these drugs using established bone turnover markers.
The purpose of this study was to confirm the stronger bone
turnover inhibitory effects of MIN, even by monthly
administration.
2. Patients and methods
The subjects were patients who had been newly diagnosed
as having primary OP between June 2013 and May 2014 based
on the primary OP diagnostic criteria (2000 revision) [11].
Written informed consent was obtained from all participants
prior to enrollment. The subjects were randomly assigned into
a group receiving 50 mg/month of MIN (MIN group) or a
group receiving 75 mg/month of RIS (RIS group). When
participants were given a diagnosis of OP, we used the enve-
lope method to randomly divide them into the MIN group or
RIS group.
A total of 32 cases (17 in the MIN group and 15 in the RIS
group) were recruited. One case in each group dropped out of
the study before the end point due to an inability to visit our
outpatient clinic on scheduled dates. Ultimately, we analyzed
the data of 30 cases (16 of MIN and 14 of RIS) obtained just
before treatment and at 4 months afterwards. Only female
patients were enrolled to avoid gender effects.
As a representative bone resorption marker, urinary NTX
was measured before drug administration and at 1, 2, and 4
months after commencement. As bone formation markers,
serum bone alkaline phosphatase (BAP) and alkaline phos-
phatase (ALP) [12] were recorded before the start of admin-
istration and 4 months afterwards.
Serum BAP was determined using a chemiluminescent
enzyme immunoassay/antibody radioimmunoassay. Serum
ALP was measured by a modified JSCC reference method by
SRL, Inc. (Tokyo, Japan). Urinary NTX was evaluated by theenzyme-linked immunosorbent assay (ELISA) (Osteomark,
Osteox International, Seattle, WA). After overnight fasting,
serum and first void urine samples were collected between
8:30 a.m. and 10:00 a.m. Immunoassays were performed by
SRL, Inc. (Tokyo, Japan). Serum calcium (Ca) was measured
using Arsenazo III (Tokyo Chemical Industry Co., Ltd.,
Tokyo, Japan). Serum phosphorus (P) was determined by
means of the Molybdate direct method by SRL, Inc. (Tokyo,
Japan).
Lumbar and bilateral hip bone mineral density (L-BMD
and H-BMD, respectively) were measured using a Dual-
energy X-ray Absorption (DXA) fan-beam bone densitom-
eter (Lunar Prodigy; GE Healthcare Bio-Sciences Corp., Pis-
cataway, NJ, USA) at the L1-4 levels of the posteroanterior
spine and bilateral hips, respectively. BMD values were
determined for the purpose of diagnosing OP in this study and
not for evaluating the effectiveness of BPs. The coefficients of
variation for the lumbar spine and femoral neck were 0.7%
and 1.1%, respectively.
Value changes of urinary NTX before treatment and at 1, 2,
and 4 months of therapy in the MIN and RIS groups were
measured and presented as the average ± standard error (SE)
(Fig. 1). Comparisons between measurement points and
baseline values in each treatment group were done using one-
sided paired t-tests with Bonferroni correction. Group com-
parisons at each measurement point were performed using
one-sided Welch's t-tests. The background data of the MIN and
RIS groups just prior to treatment are shown in Table 1 and
expressed as mean ± standard deviation (SD). The averaged
findings of age, weight, height, L-BMD, H-BMD, urinary
NTX, serum BAP, ALP, serum corrected Ca, and P were
analyzed using Welch's t-tests. Value changes of bone turnover
markers before treatment and at 4 months of therapy are
presented in Table 2. Bone turnover markers were analyzed
using one-sided Welch's t-tests, while ALP, Ca, and P were
Table 1
Background data of MIN and RIS groups before treatment.
MIN group RIS group p value
(n ¼ 16) (n ¼ 14)
Age (years) 68.2 ± 8.2 68.1 ± 6.2 0.986
Height (cm) 153.9 ± 5.4 151.8 ± 6.0 0.332
Weight (kg) 50.9 ± 5.5 48.8 ± 4.1 0.239
L-BMD (g/cm2) 0.828 ± 0.050 0.861 ± 0.096 0.248
H-BMD (g/cm2) 0.770 ± 0.090 0.723 ± 0.066 0.118
Urinary NTX (nmol BCE/
mmol Cr)
55.3 ± 18.9 59.1 ± 17.6 0.573
Serum BAP (mg/L) 17.5 ± 5.3 19.5 ± 4.9 0.297
ALP (U/L) 245.3 ± 47.3 273.6 ± 53.2 0.139
Serum corrected Ca (mg/dL) 9.30 ± 0.54 8.96 ± 0.38 0.057
P (mg/dL) 3.20 ± 0.42 3.47 ± 0.35 0.064
Values are expressed as mean ± SD.
The mean data for age, weight, height, L-BMD, H-BMD, urinary NTX, serum
BAP, ALP, serum corrected Ca, and P were analyzed using Welch's t-tests.
MIN, minodronate; RIS, risedronate; BMD, bone mineral density; NTX,
cross-linked N-telopeptide of type I collagen; BAP, bone-specific alkaline
phosphatase; ALP, alkaline phosphatase; Ca, Calcium; P, Phosphorus.
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mean ± SE. The comparative data of percent changes between
the MIN and RIS groups are shown in Table 3. Bone turnover
markers were analyzed by one-sided Welch's t-tests, while
ALP, Ca, and P were analyzed using two-sided tests. Values
are expressed as mean ± SE. A p value of <0.05 was
considered statistically significant, and indicated as * or # in
the Figure and Tables.
This study was approved by the Institutional Ethics Com-
mittee at Showa-Inan General Hospital (Procotol No.: 2015-Table 2
Value changes of bone turnover markers before treatment and at 4 months afterwa
MIN group
Before treatment After 4 months
Urinary NTX (nmol BCE/mmol Cr) 55.3 ± 4.7 20.2 ± 3.0
Serum BAP (mg/L) 17.5 ± 1.3 10.4 ± 0.8
ALP (U/L) 245.3 ± 11.8 195.3 ± 18.3
Serum corrected Ca (mg/dL) 9.30 ± 0.13 9.11 ± 0.12
P (mg/dL) 3.20 ± 0.11 2.79 ± 0.14
Values are expressed as mean ± SE.
Bone turnover markers were analyzed by one-sided Welch's t-tests, while ALP, Ca




Percent change and comparison of MIN and RIS groups.
MIN p value
Urinary NTX 63.1 ± 4.5% <0.001*
Serum BAP 38.2 ± 4.2% <0.001*
ALP 19.4 ± 7.3% 0.009*
Serum corrected Ca 2.0 ± 1.0% 0.036*
P 10.9 ± 5.8% 0.039*
Values are expressed as mean ± SE.
Bone turnover markers were analyzed by one-sided Welch's t-tests, while ALP, Ca
MIN, minodronate; RIS, risedronate; NTX, cross-linked N-telopeptide of type I coll
Calcium; P, Phosphorus.
*Statistically significant.18) and carried out in accordance with the revised 2014
Declaration of Helsinki.3. Results
The backgrounds of the patients in the MIN and RIS groups
before treatment are shown in Table 1. There were no signif-
icant differences between the groups with regard to age,
height, weight, BMD, or bone turnover markers. Both groups
had satisfactory drug compliance and exhibited no major
adverse events from BP therapy.3.1. Bone resorption markerAt 1 month of treatment, urinary NTX values were
significantly decreased by 46.5% in the MIN group and 30.3%
in the RIS group as compared with pre-treatment levels. NTX
findings were further decreased at 53.0% at 2 months and
63.1% at 4 months in the MIN group. On the other hand,
these values plateaued at 33.9% at 2 months and 30.1% at
4 months in the RIS group (Fig. 1). With respect to the
increasing ratio (IR), there was a significant difference be-
tween the groups from 2 months (p ¼ 0.025) to 4 months of
after treatment (p ¼ 0.001).
In the MIN group, urinary NTX was significantly decreased
at 4 months as compared with baseline values, from 55.3 ± 4.7
to 20.2 ± 3.0 (nmol BCE/mmol Cr) (p < 0.001), with an IR of
63.1% (p < 0.001) (Tables 2 and 3). In the RIS group, uri-
nary NTX was also significantly decreased at 4 months versusrds.
RIS group
p value Before treatment After 4 months p value
<0.001* 59.1 ± 4.7 41.2 ± 5.6 0.003*
<0.001* 19.5 ± 1.3 13.6 ± 0.9 <0.001*
0.018* 273.6 ± 14.2 227.4 ± 13.9 <0.001*
0.065 8.96 ± 0.10 8.95 ± 0.09 0.897
0.061 3.47 ± 0.09 3.16 ± 0.07 0.033*
, and P were analyzed using two-sided tests.
agen; BAP, bone-specific alkaline phosphatase; ALP, alkaline phosphatase; Ca,
RIS p value Group comparison p value
30.1 ± 8.4% 0.020* 0.001*
28.4 ± 3.8% <0.001* 0.046*
16.7 ± 2.9% <0.001* 0.369
0.0 ± 1.2% 0.970 0.236
7.8 ± 3.7% 0.028* 0.652
, and P were analyzed using two-sided tests.
agen; BAP, bone-specific alkaline phosphatase; ALP, alkaline phosphatase; Ca,
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mmol Cr) (p ¼ 0.003), with an IR of 30.1% (p ¼ 0.020)
(Tables 2 and 3). MIN had reduced urinary NTX significantly
more than had RIS at the study end point (p ¼ 0.001)
(Table 3).3.2. Bone formation markersIn the MIN group, serum BAP was significantly decreased
at 4 months as compared with baseline values, from 17.5 ± 1.3
to 10.4 ± 0.8 (mg/L) (p < 0.001), with an IR of 38.2%
(p < 0.001) (Tables 2 and 3). In RIS patients, serum BAP was
significantly decreased at 4 months versus pre-treatment
values, from 19.5 ± 1.3 to 13.6 ± 0.9 (mg/L) (p < 0.001),
with an IR of 28.4% (p < 0.001) (Tables 2 and 3). The
decrease in BAP by MIN was significantly greater than that by
RIS (p ¼ 0.046) (Table 3).
In both test groups, serum ALP values before drug
administration were similar and had significantly decreased at
4 months of BP treatment (p ¼ 0.018 and p < 0.001,
respectively) (Table 2). The IR of ALP was 19.4% for MIN
(p ¼ 0.009) and 16.7% for RIS (p < 0.001), which were
comparable (Table 3).3.3. Calcium and phosphorusIn the MIN group, serum Ca was decreased at 4 months as
compared with baseline values, from 9.30 ± 0.13 to
9.11 ± 0.12 (mg/dL) (p ¼ 0.065), with an IR of 2.0%
(p ¼ 0.036) (Table 2). This parameter did not change
remarkably for RIS (p ¼ 0.970). The IR of Ca was 2.0% for
MIN and 0.0% for RIS, which were not significantly different
(Table 3).
Serum P tended to be decreased at 4 months in the MIN
group (p ¼ 0.061), with a significant change in IR of 10.9%
(p ¼ 0.039). In the RIS group, serum P was significantly
decreased at 4 months, from 3.47 ± 0.09 to 3.16 ± 0.07 (mg/
dL) (p ¼ 0.033), with an IR of 7.8% (p ¼ 0.028). The IR of
P was 10.9% for MIN and 7.8% for RIS, which were not
significantly different (Table 3).
4. Discussion
Iwamoto et al. have described that Japanese osteoporotic
patients strongly prefer monthly BP (65.2e73.0%) to weekly
BP (13.9e15.7%) since the former was more convenient in the
MARTO study [6], wherein “dosing schedule fits lifestyle
better” was the most common reason for the preference. This
was similar to findings in Western patients [6,10,13]. Nowa-
days, monthly BPs are the mainstay of drug treatment for OP.
It is well recognized that MIN inhibits bone resorption to a
greater extent than does RIS [6,10,13]. However, to our
knowledge, there have been no reports directly comparing the
data of monthly MIN and monthly RIS. This study showed
that monthly MIN significantly and more strongly inhibited
bone resorption than did monthly RIS. We observed that uri-
nary NTX had decreased by an IR of 30.1% at 4 months byRIS treatment. Similarly, the inhibitory effects on NTX after
3e6 months of RIS treatment were approximately 30% in a
phase III trial in Japan [8]. The changes in NTX at 2 and 4
months of treatment with MIN were 53.3% and 63.1%,
respectively. In the Japanese phase III study, monthly MIN
therapy produced comparable alterations at 3e6 months of
over 50% [8]. Based on the above data, the changes in urinary
NTX in this study were in accordance with accepted values for
MIN and RIS treatments.
BPs are deposited on hydroxyapatite (HAP) and function
after being absorbed by osteoclasts. The binding affinities of
BPs to HAP in rank order have been reported as:
zoledronate > ALN > ibandronate > RIS > etidronate [15,16].
The binding affinity of MIN to HAP is very similar to that of
RIS [17].
Both MIN and RIS are third-generation nitrogen-containing
BPs that inhibit farnesyl pyrophosphate synthetase (FPPS) in
the mevalonate pathway in osteoclasts. This inhibition sup-
presses the function of osteoclasts and induces their apoptosis,
thereby inhibiting osteoclastic activity [18]. When the inhib-
itory effect on bone resorption of etidronate is set as “1”, that
of RIS is 1,000e10,000 and that of MIN is more than 10,000
[19]. It is known that the 50% inhibitory concentration of
FPPS is considerably lower for MIN than for RIS, indicating a
stronger inhibitory action of the former [18]. In a recent report
on BP binding to FPPS, MIN bound more strongly in pockets
for BP side chains and occupied more binding sites as
compared with ALN or RIS [18,19]. Here, MIN also exhibited
strong effects on bone resorption inhibition that were partic-
ularly apparent in considerations with RIS. The results of this
study supported the notion of MIN's stronger binding force
with FPPS.
Overseas, comparisons of daily (5 mg) and monthly
(150 mg) RIS demonstrated no significant difference in BMD
increases between the regimes. Thereafter, monthly RIS has
been approved at 150 mg doses [18]. Similar findings were
witnessed in Japan for daily (2.5 mg) and monthly (75 mg)
RIS [14]. On the other hand, comparative studies of RIS
indicated that the suppression of bone turnover markers by
monthly dosing were significantly weaker than that by daily
dosing both in Japan and abroad [14]. Daily (1 mg) versus
monthly (30 or 50 mg) MIN has been examined in the phase
III trial. Interestingly, monthly 50 mg MIN evoked the same
bone metabolic effects and improved BMD values as did daily
1 mg MIN, and thus monthly 50 mg MIN has been approved
in this country [19]. Comparative studies of monthly MIN
(50 mg) and monthly RIS (75 mg), which had been approved
in Japan, were also performed this time. The dosages of daily
RIS (5 mg) and monthly RIS (150 mg) approved by FDA are
double those approved in Japan. The differences in adminis-
tered doses of MIN and RIS might have affected the bone
inhibitory effects caused by the drugs in this study.
When we evaluate the early phase treatment effects of BPs
in clinical practice, bone turnover markers are useful surrogate
markers of patient response. Here, we confirmed that MIN
more strongly inhibited bone resorption than did RIS at
monthly doses. Accordingly, monthly MIN seems to suppress
174 M. Kamimura et al. / Osteoporosis and Sarcopenia 2 (2016) 170e174bone resorption faster and more strongly than RIS in OP
treatment.
5. Conclusion
Our findings showed that monthly MIN more immediately
and strongly inhibited bone resorption than did monthly RIS to
represent a more favorable anti-absorptive drug option for OP
treatment.
6. Limitations
The limitations of this study were a relatively small sample
size, no evaluation of the efficacy of the drugs on BMD values
or fracture prevention, the exclusion of male patient data.
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